Heptares Appoints Tim Tasker as Chief Medical Officer

January 9, 2014

LONDON and BOSTON, January 9, 2014 /PRNewswire/ –

Increases Focus on Clinical Development of Novel GPCR-targeted Drug


Heptares Therapeutics, the leading GPCR structure-guided drug discovery and
development company, announces the appointment of Dr Tim Tasker as Chief Medical Officer
(CMO) and Vice President of Development. Dr Tasker will lead the Company’s clinical
development activities as it advances its rich pipeline of novel GPCR-targeted agents in
multiple therapeutic areas. He takes over from Dr David McGibney, who returns to his role
as a senior clinical advisor to the Company.

Dr Tasker is a physician and clinical pharmacologist with more than 30 years of
industry experience from both large pharmaceutical and small biotechnology companies. He
spent over 20 years at GlaxoSmithKline and led all of its Phase 1 Clinical Research Units
(in the US, UK, Europe and Australia), which supported the Centres of Excellence in Drug
Discovery across all therapeutic areas. After GSK, he joined Evotec as Executive VP of
Clinical Development, at which he was instrumental in advancing novel compounds to Phase 2
proof of concept studies. Dr Tasker then set up his own consulting firm providing
high-level, early drug development expertise to companies in Europe, Australia and Japan.
Dr Tasker is a Fellow of the UK Royal College of Physicians and of the UK Faculty of
Pharmaceutical Medicine.

Tim Tasker said: “Heptares is at a very exciting stage in its development, having
recently initiated its first clinical study with the first ever fully selective M1
receptor agonist for improving cognitive function in Alzheimer’s disease patients. In
addition, Heptares has built a unique capability to discover new medicines across multiple
indications using its GPCR structure-based drug design platform. I look forward to working
with the Company as it advances these novel medicines towards clinical proof of concept
over the next few years.”

“It reflects well on Heptares that we have been able to attract a CMO of Tim’s calibre
and reputation. His experience in developing new compounds from preclinical into clinical
development is a valuable addition to Heptares as we dedicate increasing efforts to
advancing our rich pipeline of GPCR-targeted medicines,” said Malcolm Weir, Heptares CEO.
“I would like to take this opportunity to thank David McGibney for his important
contributions to building a first-class clinical development capability at Heptares and we
look forward to his continued guidance as an advisor to the company.”

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically
challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked
to a wide range of human diseases. Leveraging our proprietary structure-based drug design
technology platform, we have built an exciting pipeline of novel drug candidates with the
potential to transform the treatment of serious diseases, including Alzheimer’s disease,
ADHD, diabetes, schizophrenia, and migraine. Our pharmaceutical partners include Cubist,
MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM
Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda
Ventures. To learn more about Heptares, please visit http://www.heptares.com

HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;

StaR is a registered trademark in the EU and Japan.

SOURCE Heptares Therapeutics

Source: PR Newswire

comments powered by Disqus